Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-119) and T …
WA Keitel, KE Kester, RL Atmar, AC White Jr, NH Bond… - Vaccine, 1999 - Elsevier
WA Keitel, KE Kester, RL Atmar, AC White Jr, NH Bond, CA Holland, U Krzych, DR Palmer…
Vaccine, 1999•ElsevierThe safety and immunogenicity of 2 yeast-derived, blood-stage malaria vaccines were
evaluated in a phase l trial. Healthy adults were given 2 or 3 doses of alum-adsorbed
vaccine containing the 19 kDa carboxy-terminal fragment of the merozoite surface protein-1
(MSP-119) derived from the 3D7 or the FVO strain of Plasmodium falciparum fused to
tetanus toxoid T-helper epitopes P30 and P2. The first 2 doses of MSP-119 were well
tolerated. Hypersensitivity reactions occurred in 3 subjects after the third dose of MSP-119 …
evaluated in a phase l trial. Healthy adults were given 2 or 3 doses of alum-adsorbed
vaccine containing the 19 kDa carboxy-terminal fragment of the merozoite surface protein-1
(MSP-119) derived from the 3D7 or the FVO strain of Plasmodium falciparum fused to
tetanus toxoid T-helper epitopes P30 and P2. The first 2 doses of MSP-119 were well
tolerated. Hypersensitivity reactions occurred in 3 subjects after the third dose of MSP-119 …
The safety and immunogenicity of 2 yeast-derived, blood-stage malaria vaccines were evaluated in a phase l trial. Healthy adults were given 2 or 3 doses of alum-adsorbed vaccine containing the 19 kDa carboxy-terminal fragment of the merozoite surface protein-1 (MSP-119) derived from the 3D7 or the FVO strain of Plasmodium falciparum fused to tetanus toxoid T-helper epitopes P30 and P2. The first 2 doses of MSP-119 were well tolerated. Hypersensitivity reactions occurred in 3 subjects after the third dose of MSP-119, including bilateral injection site reactions in 2 (one with generalized skin rash), and probable histamine-associated hypotension in 1. Serum antibody responses to MSP-119 occurred in 5/16, 9/16 and 0/8 subjects given 20 μg of MSP-119, 200 μg of MSP-119, and control vaccines (hepatitis B or Td), respectively. Both MSP-119 vaccines were immunogenic in humans, but changes in formulation will be necessary to improve safety and immunogenicity profiles.
Elsevier
